XL184 (cabozantinib) for medullary thyroid carcinoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 3, 2011, Pages 407-413

  Durante, Cosimo ^a   Russo, Diego ^b   Verrienti, Antonella ^a   Filetti, Sebastiano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

medullary thyroid carcinoma; MET; RET; targeted therapy; tyrosine kinase inhibitors; VEGFRs

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; IMATINIB; MOTESANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; XL 184;

ANTINEOPLASTIC ACTIVITY; CALCITONIN BLOOD LEVEL; CELL PROLIFERATION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOCALCEMIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT REDUCTION;

ANILIDES; ANIMALS; CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 79951644977     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.559163     Document Type: Review

References (40)

1. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7
3. Chiefari E, Russo D, Giuffrida D, et al. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 1998;21:358-64 (Pubitemid 28379742)
4. Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006;2:42-52
5. Castellone MD, Verrienti A, Rao DM, et al. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 2010;73:529-34
6. Santoro M, Carlomagno F, Melillo RM, et al. Molecular mechanisms of RET activation in human neoplasia. J Endocrinol Invest 1999;22:811-19
7. Leboulleux S, Baudin E, Travagli JP, et al. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310 (Pubitemid 39287058)
8. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42 (Pubitemid 44665646)
9. Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 2010;322:2-7
10. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808 (Pubitemid 32377967)
11. Sugawara M, Geffner DL, Martinez D, et al. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2009;16:367-72
12. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010;80:592-601
13. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
14. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49 (Pubitemid 351656458)
15. De Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3466-9 (Pubitemid 47435321)
16. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
17. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
18. De Souza JA, Busaidy N, Zimrin A, et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010;28(7S):abstract 5504
19. Vandetanib (ZD6474) tablets Oncologic Drugs Advisory Committee (ODAC) meeting briefing document. FDA Public Health Advisory. Washington, DC: FDA/Oncologic Drugs Advisory Committee, 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf [Last accessed 24 January 2011]
20. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72
21. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010;28(15S):abstract 5503
22. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000;11:19-30 (Pubitemid 30307941)
23. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61 (Pubitemid 38340304)
24. Bardelli A, Basile ML, Audero E, et al. Concomitant activation of pathways downstream of Grb2 and PI3-kinase is required for MET-mediated metastasis. Oncogene 1999;18:1139-46 (Pubitemid 29085986)
25. Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23 (Pubitemid 37339965)
26. Kurzrock R, Cohen EE, Sherman SI, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010;28(15S):abstract 5502
27. Salgia R, Hong D, Sherman SI, et al. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Mol Cancer Ther 2007;19:abstract A152
28. Salgia R, Hong DS, Camacho LH, et al. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2007;25(18S):abstract 14031
29. Salgia R, Sherman S, Hong DS, et al. Phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008;26(15S):abstract 3522
30. Kurzrock R, Sherman S, Hong D, et al. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) [abstract 379]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theurapeutics; Geneva; 2008
31. Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-21
32. Murakami H, Yamamura Y, Shimono Y, et al. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002;277:32781-90 (Pubitemid 34984787)
33. De Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-60 (Pubitemid 44213230)
34. Plaza-Menacho I, Burzynski G, de Groot JW, et al. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 2006;22:627-36 (Pubitemid 44602269)
35. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-63 (Pubitemid 39178858)
36. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90 (Pubitemid 47574858)
37. Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006;13:3483-92 (Pubitemid 44873742)
38. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43 (Pubitemid 46799492)
39. Sennino B, Naylor RM, Tabruyn SP, et al. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-TAG2 mice after inhibition of VEGFR plus C-MET by XL 184. Mol Cancer Ther 2009;8:abstract 13
40. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48